TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06341621
Drug: 3-year abemaciclib without chemo
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: aromatase inhibitors (± ovarian suppression) plus 3-year abemaciclib (100mg bid) without chemotherapy.
Study: NCT05914285
Drug: 5ml of inhaled normal saline
Normalized name: NS-2
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 30 minutes after the completion of drug inhalation.
Study: NCT04920968
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland. Patients in experimental arm will receive obinutuzumab .Obinutuzumab: 1000 mg i.v. (first infusion divided into 100 mg on d. 1 and 900 mg on d. 2).
Study: NCT04920968
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy will be conducted according to PALG ALL7 protocol, which is considered a standard of care in Poland.The protocol includes the use of rituximab in combination chemotherapy. Rituximab: 375 mg/m2 intravenously (i.v.)
Study: NCT06265272
Drug: Injection of a gadolinium contrast agen
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be requested to have an injection of a gadolinium contrast agent, which may be either Gadavist (Bayer, Whippany, NJ, USA), Eovist (Bayer, Whippany, NJ, USA), or Dotarem (Guerbet, Princeton, NJ, USA) (ancillary drugs).~* About halfway through the examination, the same intravenous catheter used to inject the radiotracer will be used to inject the MRI contrast agent;~* After being positioned on the PET/MRI table, the nuclear medicine technicians will connect the patient to the MRI-safe power-injector; - The catheter will be flushed before and after injection with 0.9% saline solution;
Study: NCT05104567
Drug: THOR-707
Normalized name: IL-2 variant THOR-707
DrugBank: Pegenzileukin (DB17495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion: intravenous infusion
Study: NCT05104567
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for infusion: intravenous infusion
Study: NCT05104567
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution for infusion: intravenous infusion
Study: NCT05884463
Drug: 18F-FAPI
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of one dosage of 18F-FAPI.
Study: NCT05884463
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection of one dosage of 18F-FDG.
Study: NCT05953909
Drug: nab-paclitaxel based regimen
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles.
Study: NCT06144736
Drug: Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient is given the option for an adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin two to four weeks after RA-RPLND
Study: NCT06522555
Drug: polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Polatuzumab vedotin, Zanubrutinib, Lenalidomide and Rituximab (Pola-ZR2)~Induction therapy:~The Pola-ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Polatuzumab vedotin 1.8 mg/kg, day 2 on the 1st cycle and day 1 on the 2nd to 6th cycle; Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years.
Study: NCT06522555
Drug: zanubrutinib, rituximab and lenalidomide
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Zanubrutinib, Lenalidomide and Rituximab (ZR2)~Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years.
Study: NCT06499233
Drug: Trimethoprim/Sulfamethoxazole
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis; Treatment duration: at least 28 days, adjusted by the clinician based on the severity of the patient's condition, the patient's tolerance to the drug and treatment willingness).
Study: NCT05254639
Drug: DONEPEZIL
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg daily for 4 weeks + 10 mg daily for 12 weeks according to tolerance or efficacy
Study: NCT04946929
Drug: Ticagrelor Oral Tablet [Brilinta]
Normalized name: ticagrelor Oral Tablet [Brilinta]
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor, 2-3mg/kg, 12h, p.o.
Study: NCT06014138
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation
Study: NCT06014138
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations
Study: NCT06621017
Drug: ROSE-010 99 mcg
Normalized name: Rose Oil
DrugBank: Evening primrose oil (DB11358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-cutaneous injection of ROSE-010 solution
Study: NCT06621017
Drug: ROSE-010 150 mcg
Normalized name: Rose Oil
DrugBank: Evening primrose oil (DB11358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-cutaneous injection of ROSE-010 solution
Study: NCT06463652
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclogest® 200mg, Actavis, United Kingdom, applied once daily at bedtime.
Study: NCT04892693
Drug: Talazoparib Oral Capsule
Normalized name: talazoparib Oral Capsule
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Patients will receive Talazoparib 1 mg orally once daily continuously, with or without food. Laboratory values will be monitored every 4 weeks until progression or unacceptable toxicity. Dose modifications should be made based on the observed toxicity
Study: NCT06098872
Drug: Trametinib tablet
Normalized name: Trametinib Tablets
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug is supplied in 2mg and 0.5 mg tablets
Study: NCT05277675
Drug: Tislelizumab/Sintilimab+Lenvatinib/Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immune checkpoint inhibitor (tislelizumab/sintilimab) combined with anti-angiogenic drugs (lenvatinib/bevacizumab) used as neoadjuvant therapy
Study: NCT06016530
Drug: Dexamethasone Supplementation
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone belongs to the drug class of corticosteroids. It is a synthetic glucocorticoid that activates glucocorticoid receptor (GR) and the hypothalamic-pituitary-adrenal (HPA) axis selectively.~Following the administration of 1 mg of dexamethasone as a pharmacological stressor, individual fluctuations of various metabolites will be measured throughout the day (12 hours) for each participant under a standardized diet. To facilitate this, blood samples will be collected and processed into plasma or peripheral blood mononuclear cells (PBMCs).
Study: NCT05955001
Drug: Tadalafil 5mg / Placebo
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients after Holmium laser Enucleation of Prostate (HoLEP) will receive single daily dose of Tadalafil for 3 months and compared to Placebo
Study: NCT06313086
Drug: DP303c
Normalized name: ADC DP303c
DrugBank: DP-303c (DB17212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT06313086
Drug: trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous injection
Study: NCT05129137
Drug: nefopam hydrochloride 30mg X2
Normalized name: nefopam 30 MG
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nefopam hydrochloride 30mg X2
Study: NCT05129137
Drug: paracetamol 500 mg X2
Normalized name: Soothanol X2
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: paracetamol 500 mg X2
Study: NCT05129137
Drug: Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
Study: NCT04799548
Drug: Transcatheter Arterial Chemoembolization
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy.~TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.~SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid.
Study: NCT04799548
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.
Study: NCT04806906
Drug: CC-486
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product will be dispensed on Day 1 of each treatment cycle. 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
Study: NCT05803070
Drug: Topical Cetirizine 1 %
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical cetirizine belongs to anti histamines group
Study: NCT06626152
Drug: Apo-levocarb
Normalized name: varenicline
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As above.
Study: NCT05593757
Drug: Quinidine
Normalized name: Quinidine
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral quinidine
Study: NCT05593757
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral verapamil
Study: NCT05803070
Drug: Topical betamethasone valerate 0.1%
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical betamethasone valerate belongs to corticosteroids group
Study: NCT04789291
Drug: BI 1595043
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet).
Study: NCT06370728
Drug: Orforglipron
Normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06370728
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05573477
Drug: ATB-1011
Normalized name: ATB-346
DrugBank: ATB-346 (DB15377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05573477
Drug: ATB-1012
Normalized name: ATB-346
DrugBank: ATB-346 (DB15377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT05573477
Drug: ATB-1013
Normalized name: ATB-346
DrugBank: ATB-346 (DB15377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT04724629
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg of indirect IL-6 inhibitor
Study: NCT04351373
Drug: Fluorescein Sodium
Normalized name: Fluorescein Sodium
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration 1 mg/kg initial dosing if insufficient additional doses of 1 mg/kg may be administered.
Study: NCT05532072
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rapamycin plus Methylprednisolone
Study: NCT05532072
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone Alone
Study: NCT04718285
Drug: Montelukast Oral Tablet
Normalized name: montelukast Oral Tablet
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3x10 mg oral montelukast first day and other 13 days 1 x 10 mg montelukast
Study: NCT04718285
Drug: Montelukast plus Favicovir (Favipiravir)
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast first day and rest of 13 days 1 x 10mg, concurrently.
Study: NCT04718285
Drug: Favicovir (Standard Treatment)
Normalized name: Favilavir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
Study: NCT05855590
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/kg intravenous single dose
Study: NCT06034925
Drug: Maribavir
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: maribavir 400mg twice daily
Study: NCT06034925
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: valganciclovir 900mg once daily
Study: NCT05764538
Drug: DAOIB
Normalized name: Dapagliflozin and Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation
Study: NCT06665178
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administer Sacituzumab Govitecan (SG) at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle. SG should not be administered as an IV push or bolus.
Study: NCT05644223
Drug: edaravone dexborneol
DrugBank: Borneol (DB11288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous edaravone dexborneol 37.5mg twice daily
Study: NCT05019846
Drug: Triptorelin Embonate
Normalized name: Triptorelin embonate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single administration before SRT starting
Study: NCT05019846
Drug: Bicalutamide 50 mg
Normalized name: bicalutamide 50 MG
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 dose each day, 7 days before LHRH until 10 days after LHRH administration
Study: NCT06375616
Drug: Nafamostat Mesylate
Normalized name: mesylate
DrugBank: Nafamostat (DB12598)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: During RRT, a priming dose of 20 mg of nafamostat mesylate (NM) is administered before initiation of the procedure. Upon starting the machine, there is no loading dose, but a maintenance infusion rate of 25 mg/h of NM is maintained. NM is discontinued in the last half hour before the end of the RRT session.
Study: NCT06375616
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During RRT, a priming dose of 50 mg of unfractionated heparin (UFH) is administered before initiation of the procedure. Upon starting the machine, a loading dose of 0.2 mg/kg of UFH is given, followed by a maintenance infusion rate of 0.1 mg/kg/h of UFH. The anticoagulant is discontinued in the last half hour before the end of the RRT session.
Study: NCT06617247
Drug: Intervention1: Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Os cuidadores randomizados para esta intervenção usarão CBD oral 300 mg (ou seja, 150 mg, duas vezes ao dia) por quatro semanas. A substância será fornecida gratuitamente pela empresa Ease Labs e será administrada em cápsulas para promover o cegamento. Esta posologia foi baseada no estudo, no qual o CBD nesta dosagem e forma de apresentação provou ser seguro e eficaz na redução de indicadores de burnout em profissionais de saúde da linha de frente da COVID-19. A segurança do uso do CBD também foi relatada em estudos anteriores conduzidos com humanos. Os efeitos colaterais do uso do CBD são raros, incluindo sintomas leves e toleráveis (por exemplo, tontura, sonolência, fadiga, letargia, náusea, dor de cabeça, febre e alterações sensoriais).
Study: NCT05287308
Drug: epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.
Study: NCT05287308
Drug: pirarubicin
Normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.
Study: NCT05287308
Drug: albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: albumin-bound paclitaxel 260mg/m2, i.v., d1, q3w; 260mg/m2, i.v., d1, q2w; or 125mg/m2, i.v., d1, qw.
Study: NCT05287308
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel 175mg/m2, i.v., d1, q3w; 175mg/m2, i.v., d1, q2w; or 80mg/m2, i.v., d1, qw.
Study: NCT05287308
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 80\~100mg/m2, i.v., d1, q3w.
Study: NCT04498325
Drug: NT-I7
Normalized name: NT-I7
DrugBank: Efineptakin alfa (DB16395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied by study
Study: NCT04936854
Drug: Sirolimus 1 mg Oral Tablet
Normalized name: SIROLIMUS 1 mg ORAL TABLET
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 mg Sirolimus (two 1 mg tablets) on the first day, followed by 0,5 mg Sirolimus (half 1 mg tablet) per day for 12 weeks.
Study: NCT04936854
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg Methylprednisolone intravenously once a week for 6 weeks, followed by 250 mg once a week for 6 weeks. Total period of treatment 12 weeks.
Study: NCT05578950
Drug: itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg two capsules of itraconazole were givev twice daily to 50 patients in group A for one week per month . baseline LFTs were also monitered
Study: NCT05578950
Drug: terbinafine
Normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one 250 mg tablet of terbinafine were given once daily to 50 patients in group B for 12 weeks continously
Study: NCT05571644
Drug: mFOLFOXIRI + Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
Study: NCT06018025
Drug: CGRP antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with CGRP antibody for 4 months
Study: NCT05496959
Drug: Lutetium Lu-177 PNT2002
Normalized name: Lutetium dotatate Lu-177
DrugBank: Lutetium Lu-177 (DB13982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05657990
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg one time daily after a meal for seven days prior to surgery. Post-surgery, an ultrasound of the bladder will be completed approximately six hours after surgery to assess the bladder. If the bladder ultrasound shows more than 400 cc of urine in the bladder, or if the study subject passes urine on his own and there is more than 100cc or less than 400 cc of urine left in the bladder, he will be encouraged to try to pass urine. Study subject will be monitored for two additional hours. If a study subject is unable to pass urine at this time or the bladder has 400 cc or more of urine left in it, he will have an intermittent catheter (in and out) to drain urine. If the bladder has greater than 500 cc (which is approximately 16 and two-thirds ounces) per catheterization for more than 24 hours, and the study subject cannot pass urine, an indwelling catheter may be considered.
Study: NCT04803422
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study aims to test whether oral antibiotics is non-inferior compared to intravenous antibiotics.
Study: NCT06649422
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The 14-day blinatumomab combined with reduced-dose chemotherapy is used for the induction treatment of newly diagnosed Ph-chromosome negative acute B-lymphoblastic leukemia.